Global Osteosarcoma Market Research Report—Forecast till 2025
出 版 商：Market Research Future
出版日期：2020/12/01
頁 數：103頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
USD 6,250 (Global-User License)
Global Osteosarcoma Market: Information by Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis & Treatment (Treatment and Diagnosis), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations), by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025
Market Analysis
Osteosarcoma Market is expected to register a CAGR of 6.09% to reach USD 791.08 Million by the year 2025. Osteosarcoma is a common type of bone cancer which is developed in cells which are responsible for formation of bones. In very rare conditions osteosarcoma happens in soft tissue outside the bones. Usually, it mostly occurs in teenagers, young adults, and older adult population. The global osteosarcoma market is predominantly driven by a high incidence of osteosarcoma, increasing expenditure on oncology medicine and research, and growing demand for new treatments. Nevertheless, the high cost of treatment and side-effects of chemotherapy impede the growth of the market. The Global Osteosarcoma Market is taking shape due to a higher incidence of osteosarcoma. For example, the prevalence of primary bone cancer is growing across the world. Under national Institutes of Health (NIH), estimation of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. As per the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in the year 2018. Additionally, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. The cumulative prevalence of osteosarcoma along with the increasing geriatric population are driving the global osteosarcoma market.
Market Segmentation
The Global Osteosarcoma Market has been segmented into type, diagnosis & treatment, end user, and region. Based on type the Global Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extra skeletal osteosarcoma. Intramedullary osteosarcoma has been estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Typically, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites impacted by intramedullary osteosarcoma. Based on diagnosis & treatment, the global osteosarcoma market has been divided into the treatment and diagnosis. The treatment segment is further divided into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment contains a limb-sparing surgery and amputation. The diagnosis segment is even more segmented into imaging, biopsies, and blood tests. The imaging segment comprises computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others. Based on end-user, the global osteosarcoma market has been divided into hospitals & clinics, diagnostic centres, and academic & research organizations. Its hold biggest market share could be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, as well as the availability of skilled and qualified professionals.
Regional Analysis
The Global Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas represent a market share of 40.02% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest global osteosarcoma market in the year 2018. The Europe region is even more segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been divided into the Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region was classified as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market. The market in the Middle East & Africa is likely to show minimum growth by factors such as limited access to and higher availability of treatment facilities. However, the high prevalence of bone cancer population will support growth of the market in the region during the forecast period.
Major Players
Academic research institutes, Pharmaceutical companies, Biotechnology companies and Market research & consulting firms are some of the projected onlookers for the Global Osteosarcoma Market. Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. are some of the major players in the Global Osteosarcoma Market.
Market Analysis
Osteosarcoma Market is expected to register a CAGR of 6.09% to reach USD 791.08 Million by the year 2025. Osteosarcoma is a common type of bone cancer which is developed in cells which are responsible for formation of bones. In very rare conditions osteosarcoma happens in soft tissue outside the bones. Usually, it mostly occurs in teenagers, young adults, and older adult population. The global osteosarcoma market is predominantly driven by a high incidence of osteosarcoma, increasing expenditure on oncology medicine and research, and growing demand for new treatments. Nevertheless, the high cost of treatment and side-effects of chemotherapy impede the growth of the market. The Global Osteosarcoma Market is taking shape due to a higher incidence of osteosarcoma. For example, the prevalence of primary bone cancer is growing across the world. Under national Institutes of Health (NIH), estimation of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. As per the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in the year 2018. Additionally, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. The cumulative prevalence of osteosarcoma along with the increasing geriatric population are driving the global osteosarcoma market.
Market Segmentation
The Global Osteosarcoma Market has been segmented into type, diagnosis & treatment, end user, and region. Based on type the Global Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extra skeletal osteosarcoma. Intramedullary osteosarcoma has been estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Typically, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites impacted by intramedullary osteosarcoma. Based on diagnosis & treatment, the global osteosarcoma market has been divided into the treatment and diagnosis. The treatment segment is further divided into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment contains a limb-sparing surgery and amputation. The diagnosis segment is even more segmented into imaging, biopsies, and blood tests. The imaging segment comprises computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others. Based on end-user, the global osteosarcoma market has been divided into hospitals & clinics, diagnostic centres, and academic & research organizations. Its hold biggest market share could be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, as well as the availability of skilled and qualified professionals.
Regional Analysis
The Global Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas represent a market share of 40.02% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest global osteosarcoma market in the year 2018. The Europe region is even more segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been divided into the Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region was classified as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market. The market in the Middle East & Africa is likely to show minimum growth by factors such as limited access to and higher availability of treatment facilities. However, the high prevalence of bone cancer population will support growth of the market in the region during the forecast period.
Major Players
Academic research institutes, Pharmaceutical companies, Biotechnology companies and Market research & consulting firms are some of the projected onlookers for the Global Osteosarcoma Market. Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. are some of the major players in the Global Osteosarcoma Market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 18
1.2 MARKET SYNOPSIS 18
1.3 KEY CONTRIBUTING FACTORS 19
2 MARKET INTRODUCTION
2.1 DEFINITION 20
2.2 SCOPE OF THE STUDY 20
2.3 RESEARCH OBJECTIVE 20
2.4 MARKET STRUCTURE 21
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 22
3.2 PRIMARY RESEARCH 24
3.3 SECONDARY RESEARCH 25
3.4 MARKET SIZE ESTIMATION 25
3.5 FORECAST MODEL 27
3.6 LIST OF ASSUMPTIONS 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA 30
4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 30
4.2.3 RISING DEMAND FOR NEW TREATMENTS 30
4.3 RESTRAINTS 31
4.3.1 HIGH COST OF TREATMENT 31
4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY 31
4.4 OPPORTUNITIES 32
4.4.1 ENTERING DEVELOPING ECONOMIES 32
4.5 MACROECONOMIC INDICATORS 33
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 34
5.1.1 BARGAINING POWER OF SUPPLIERS 35
5.1.2 BARGAINING POWER OF BUYERS 35
5.1.3 THREAT OF NEW ENTRANTS 35
5.1.4 THREAT OF SUBSTITUTES 35
5.1.5 INTENSITY OF RIVALRY 35
5.2 VALUE CHAIN ANALYSIS 36
5.2.1 R&D AND DESIGNING 37
5.2.2 MANUFACTURING 37
5.2.3 DISTRIBUTION 37
5.2.4 MARKETING & SALES 37
5.2.5 POST-SALES MONITORING 37
5.3 EPIDEMIOLOGY DATA 38
5.4 CLINICAL TRIALS ANALYSIS 39
5.5 PIPELINE ANALYSIS 41
5.5.1 PEMETREXED 41
5.5.2 INHALED LIPID CISPLATIN 41
6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE
6.1 OVERVIEW 42
6.2 INTRAMEDULLARY OSTEOSARCOMA 43
6.3 JUXTACORTICAL OSTEOSARCOMA 44
6.4 EXTRASKELETAL OSTEOSARCOMA 44
7 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW 45
7.2 TREATMENT 46
7.2.1 CHEMOTHERAPY 47
7.2.2 SURGERY 47
7.2.3 RADIATION THERAPY 47
7.3 DIAGNOSIS 48
7.3.1 IMAGING 48
7.3.2 BIOPSIES 49
7.3.3 BLOOD TESTS 50
8 GLOBAL OSTEOSARCOMA MARKET, BY END USER
8.1 OVERVIEW 51
8.2 HOSPITALS & CLINICS 52
8.3 DIAGNOSTIC CENTERS 52
8.4 ACADEMIC & RESEARCH ORGANIZATIONS 53
9 GLOBAL OSTEOSARCOMA MARKET, BY REGION
9.1 OVERVIEW 54
9.2 AMERICAS 56
9.2.1 NORTH AMERICA 60
9.2.2 LATIN AMERICA 69
9.3 EUROPE 73
9.3.1 WESTERN EUROPE 76
9.3.2 EASTERN EUROPE 99
9.4 ASIA-PACIFIC 103
9.4.1 JAPAN 107
9.4.2 CHINA 110
9.4.3 INDIA 113
9.4.4 SOUTH KOREA 116
9.4.5 REST OF ASIA-PACIFIC 119
9.5 MIDDLE EAST & AFRICA 123
9.5.1 MIDDLE EAST 127
9.5.2 AFRICA 130
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 134
10.2 KEY DEVELOPMENTS 134
11 COMPANY PROFILES
11.1 PFIZER INC. 136
11.1.1 COMPANY OVERVIEW 136
11.1.2 FINANCIAL OVERVIEW 137
11.1.3 PRODUCTS/SERVICES OFFERED 137
11.1.4 KEY DEVELOPMENTS 138
11.1.5 SWOT ANALYSIS 138
11.1.6 KEY STRATEGIES 138
11.2 BRISTOL-MYERS SQUIBB COMPANY 139
11.2.1 COMPANY OVERVIEW 139
11.2.2 FINANCIAL OVERVIEW 139
11.2.3 PRODUCTS/SERVICES OFFERED 140
11.2.4 KEY DEVELOPMENTS 140
11.2.5 SWOT ANALYSIS 140
11.2.6 EY STRATEGIES 141
11.3 ELI LILLY AND COMPANY 142
11.3.1 COMPANY OVERVIEW 142
11.3.2 FINANCIAL OVERVIEW 143
11.3.3 PRODUCTS/SERVICES OFFERED 143
11.3.4 KEY DEVELOPMENTS 143
11.3.5 SWOT ANALYSIS 144
11.3.6 KEY STRATEGIES 144
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 145
11.4.1 COMPANY OVERVIEW 145
11.4.2 FINANCIAL OVERVIEW 146
11.4.3 PRODUCTS/SERVICES OFFERED 146
11.4.4 KEY DEVELOPMENTS 146
11.4.5 SWOT ANALYSIS 147
11.4.6 KEY STRATEGIES 147
11.5 BAXTER INTERNATIONAL 148
11.5.1 COMPANY OVERVIEW 148
11.5.2 FINANCIAL OVERVIEW 148
11.5.3 PRODUCTS/SERVICES OFFERED 149
11.5.4 KEY DEVELOPMENTS 149
11.5.5 SWOT ANALYSIS 150
11.5.6 KEY STRATEGIES 150
11.6 NOVARTIS AG 151
11.6.1 COMPANY OVERVIEW 151
11.6.2 FINANCIAL OVERVIEW 151
11.6.3 PRODUCTS/SERVICES OFFERED 152
11.6.4 KEY DEVELOPMENTS 152
11.6.5 SWOT ANALYSIS 153
11.6.6 KEY STRATEGIES 153
11.7 AUROBINDO PHARMA LIMITED 154
11.7.1 COMPANY OVERVIEW 154
11.7.2 FINANCIAL OVERVIEW 154
11.7.3 PRODUCTS/SERVICES OFFERED 155
11.7.4 KEY DEVELOPMENTS 155
11.7.5 SWOT ANALYSIS 156
11.7.6 KEY STRATEGIES 156
11.8 HIKMA PHARMACEUTICALS PLC 157
11.8.1 COMPANY OVERVIEW 157
11.8.2 FINANCIAL OVERVIEW 157
11.8.3 PRODUCTS/SERVICES OFFERED 158
11.8.4 KEY DEVELOPMENTS 158
11.8.5 SWOT ANALYSIS 159
11.8.6 KEY STRATEGIES 159
11.9 MYLAN NV 160
11.9.1 COMPANY OVERVIEW 160
11.9.2 FINANCIAL OVERVIEW 161
11.9.3 PRODUCTS/SERVICES OFFERED 162
11.9.4 KEY DEVELOPMENTS 162
11.9.5 SWOT ANALYSIS 163
11.9.6 KEY STRATEGIES 163
11.10 ADVAXIS, INC. 164
11.10.1 COMPANY OVERVIEW 164
11.10.2 FINANCIAL OVERVIEW 164
11.10.3 PRODUCTS/SERVICES OFFERED 164
11.10.4 KEY DEVELOPMENTS 165
11.10.5 SWOT ANALYSIS 165
11.10.6 KEY STRATEGIES 166
12 APPENDIX
12.1 REFERENCES 167
12.2 RELATED REPORTS 167
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 18
1.2 MARKET SYNOPSIS 18
1.3 KEY CONTRIBUTING FACTORS 19
2 MARKET INTRODUCTION
2.1 DEFINITION 20
2.2 SCOPE OF THE STUDY 20
2.3 RESEARCH OBJECTIVE 20
2.4 MARKET STRUCTURE 21
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 22
3.2 PRIMARY RESEARCH 24
3.3 SECONDARY RESEARCH 25
3.4 MARKET SIZE ESTIMATION 25
3.5 FORECAST MODEL 27
3.6 LIST OF ASSUMPTIONS 28
4 MARKET DYNAMICS
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA 30
4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 30
4.2.3 RISING DEMAND FOR NEW TREATMENTS 30
4.3 RESTRAINTS 31
4.3.1 HIGH COST OF TREATMENT 31
4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY 31
4.4 OPPORTUNITIES 32
4.4.1 ENTERING DEVELOPING ECONOMIES 32
4.5 MACROECONOMIC INDICATORS 33
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 34
5.1.1 BARGAINING POWER OF SUPPLIERS 35
5.1.2 BARGAINING POWER OF BUYERS 35
5.1.3 THREAT OF NEW ENTRANTS 35
5.1.4 THREAT OF SUBSTITUTES 35
5.1.5 INTENSITY OF RIVALRY 35
5.2 VALUE CHAIN ANALYSIS 36
5.2.1 R&D AND DESIGNING 37
5.2.2 MANUFACTURING 37
5.2.3 DISTRIBUTION 37
5.2.4 MARKETING & SALES 37
5.2.5 POST-SALES MONITORING 37
5.3 EPIDEMIOLOGY DATA 38
5.4 CLINICAL TRIALS ANALYSIS 39
5.5 PIPELINE ANALYSIS 41
5.5.1 PEMETREXED 41
5.5.2 INHALED LIPID CISPLATIN 41
6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE
6.1 OVERVIEW 42
6.2 INTRAMEDULLARY OSTEOSARCOMA 43
6.3 JUXTACORTICAL OSTEOSARCOMA 44
6.4 EXTRASKELETAL OSTEOSARCOMA 44
7 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW 45
7.2 TREATMENT 46
7.2.1 CHEMOTHERAPY 47
7.2.2 SURGERY 47
7.2.3 RADIATION THERAPY 47
7.3 DIAGNOSIS 48
7.3.1 IMAGING 48
7.3.2 BIOPSIES 49
7.3.3 BLOOD TESTS 50
8 GLOBAL OSTEOSARCOMA MARKET, BY END USER
8.1 OVERVIEW 51
8.2 HOSPITALS & CLINICS 52
8.3 DIAGNOSTIC CENTERS 52
8.4 ACADEMIC & RESEARCH ORGANIZATIONS 53
9 GLOBAL OSTEOSARCOMA MARKET, BY REGION
9.1 OVERVIEW 54
9.2 AMERICAS 56
9.2.1 NORTH AMERICA 60
9.2.2 LATIN AMERICA 69
9.3 EUROPE 73
9.3.1 WESTERN EUROPE 76
9.3.2 EASTERN EUROPE 99
9.4 ASIA-PACIFIC 103
9.4.1 JAPAN 107
9.4.2 CHINA 110
9.4.3 INDIA 113
9.4.4 SOUTH KOREA 116
9.4.5 REST OF ASIA-PACIFIC 119
9.5 MIDDLE EAST & AFRICA 123
9.5.1 MIDDLE EAST 127
9.5.2 AFRICA 130
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 134
10.2 KEY DEVELOPMENTS 134
11 COMPANY PROFILES
11.1 PFIZER INC. 136
11.1.1 COMPANY OVERVIEW 136
11.1.2 FINANCIAL OVERVIEW 137
11.1.3 PRODUCTS/SERVICES OFFERED 137
11.1.4 KEY DEVELOPMENTS 138
11.1.5 SWOT ANALYSIS 138
11.1.6 KEY STRATEGIES 138
11.2 BRISTOL-MYERS SQUIBB COMPANY 139
11.2.1 COMPANY OVERVIEW 139
11.2.2 FINANCIAL OVERVIEW 139
11.2.3 PRODUCTS/SERVICES OFFERED 140
11.2.4 KEY DEVELOPMENTS 140
11.2.5 SWOT ANALYSIS 140
11.2.6 EY STRATEGIES 141
11.3 ELI LILLY AND COMPANY 142
11.3.1 COMPANY OVERVIEW 142
11.3.2 FINANCIAL OVERVIEW 143
11.3.3 PRODUCTS/SERVICES OFFERED 143
11.3.4 KEY DEVELOPMENTS 143
11.3.5 SWOT ANALYSIS 144
11.3.6 KEY STRATEGIES 144
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 145
11.4.1 COMPANY OVERVIEW 145
11.4.2 FINANCIAL OVERVIEW 146
11.4.3 PRODUCTS/SERVICES OFFERED 146
11.4.4 KEY DEVELOPMENTS 146
11.4.5 SWOT ANALYSIS 147
11.4.6 KEY STRATEGIES 147
11.5 BAXTER INTERNATIONAL 148
11.5.1 COMPANY OVERVIEW 148
11.5.2 FINANCIAL OVERVIEW 148
11.5.3 PRODUCTS/SERVICES OFFERED 149
11.5.4 KEY DEVELOPMENTS 149
11.5.5 SWOT ANALYSIS 150
11.5.6 KEY STRATEGIES 150
11.6 NOVARTIS AG 151
11.6.1 COMPANY OVERVIEW 151
11.6.2 FINANCIAL OVERVIEW 151
11.6.3 PRODUCTS/SERVICES OFFERED 152
11.6.4 KEY DEVELOPMENTS 152
11.6.5 SWOT ANALYSIS 153
11.6.6 KEY STRATEGIES 153
11.7 AUROBINDO PHARMA LIMITED 154
11.7.1 COMPANY OVERVIEW 154
11.7.2 FINANCIAL OVERVIEW 154
11.7.3 PRODUCTS/SERVICES OFFERED 155
11.7.4 KEY DEVELOPMENTS 155
11.7.5 SWOT ANALYSIS 156
11.7.6 KEY STRATEGIES 156
11.8 HIKMA PHARMACEUTICALS PLC 157
11.8.1 COMPANY OVERVIEW 157
11.8.2 FINANCIAL OVERVIEW 157
11.8.3 PRODUCTS/SERVICES OFFERED 158
11.8.4 KEY DEVELOPMENTS 158
11.8.5 SWOT ANALYSIS 159
11.8.6 KEY STRATEGIES 159
11.9 MYLAN NV 160
11.9.1 COMPANY OVERVIEW 160
11.9.2 FINANCIAL OVERVIEW 161
11.9.3 PRODUCTS/SERVICES OFFERED 162
11.9.4 KEY DEVELOPMENTS 162
11.9.5 SWOT ANALYSIS 163
11.9.6 KEY STRATEGIES 163
11.10 ADVAXIS, INC. 164
11.10.1 COMPANY OVERVIEW 164
11.10.2 FINANCIAL OVERVIEW 164
11.10.3 PRODUCTS/SERVICES OFFERED 164
11.10.4 KEY DEVELOPMENTS 165
11.10.5 SWOT ANALYSIS 165
11.10.6 KEY STRATEGIES 166
12 APPENDIX
12.1 REFERENCES 167
12.2 RELATED REPORTS 167
